White House Targets Drug Pricing and Microplastics in Dual Policy Push

What Happened?

The White House rolled out a two-part policy targeting prescription drug pricing and contaminants in drinking water, tying together cost and health concerns in a single push. On the pharmaceutical side, the White House announced tariffs of up to 100% on imported patented drugs and active pharmaceutical ingredients (APIs) from companies that do not move production to the U.S. or adopt Most-Favored-Nation (MFN) pricing. Companies that commit to domestic manufacturing face a reduced 20% tariff.

The policy is being justified under Section 232 of the Trade Expansion Act on national security grounds. The administration argues the U.S. is too dependent on foreign drug production, with more than half of patented drugs and roughly 85% of APIs currently imported. The goal is to bring manufacturing back to the U.S. while lowering prices by tying them more closely to what other countries pay.

At the same time, the Environmental Protection Agency is moving to regulate emerging contaminants in drinking water. Microplastics and pharmaceuticals have been added to the agency’s Sixth Contaminant Candidate List, marking the first time they are being considered in grouped categories for potential regulation under the Safe Drinking Water Act. The EPA also released health benchmarks for 374 pharmaceuticals to guide local water systems.

Why It Matters

The change in drug pricing directly targets how and where drugs are made, using tariffs to force changes in supply chains. By tying pricing to international benchmarks and linking it to domestic production, the administration is trying to address two issues at once: exorbitant costs for consumers and reliance on foreign manufacturing.

A $2.1 Trillion Energy Breakthrough Years in the Making

John D. Rockefeller’s empire would be worth $435 billion in today’s dollars. But “oil money” is old news, and what’s next might surprise you: the $2.1T opportunity in “clean coal.” 

Patented tech from Frontieras is making this possible. It can reform coal into hydrogen and other valuable commodities (like Rockefeller did with oil) without burning it.

They’ve now officially purchased land for their $850m flagship facility in West Virginia, praised by the state’s governor for creating up to 2,000 potential new jobs. 

With a White House that favors domestic energy and the Nasdaq ticker FASF reserved, this could be investors’ last chance at the current valuation.

You have until April 9 to invest in Frontieras at $7.77/share.*

It’s an approach that comes with trade-offs. Tariffs at this scale can raise costs in the short term if companies pass them on, even as they are meant to pressure long-term changes. Bringing production back to the U.S. also takes time, so the supply chain may need adjustments before any benefits appear.

On the environmental side, the EPA’s announcement is notable because it formally brings microplastics and pharmaceutical residues into the regulatory pipeline. These substances have been widely detected in drinking water and human bodies, but have not had enforceable federal limits.

The agency is scaling back earlier plans on PFAS chemicals, proposing to require filtration for two types by 2031 instead of six by 2029, which changes how aggressively certain contaminants are addressed.

How It Affects You

Tariffs are likely to push drug prices higher in the short term as companies adjust and pass through added costs. But over a longer stretch of time, if production moves back to the U.S. and pricing is pulled closer to international benchmarks, those pressures could ease, but only if companies follow through on those changes.

While changes to water standards tend to move more quietly, they carry big consequences for local systems. Bringing microplastics and pharmaceuticals into the regulatory process means utilities will more than likely need to upgrade filtration, expand testing, and adjust treatment methods, with those costs often working their way into water bills or public infrastructure spending.

The proposed changes create a more concrete standard for exposure, which has largely been left undefined. While microplastics and pharmaceutical residues are already present in water and food and pose a significant issue in their own right, regulations are beginning to set actual thresholds and require action when those limits are exceeded.

*Disclaimer: This is a paid advertisement for Frontieras’s Regulation A offering. Please read the offering circular at https://invest.frontieras.com/

Reservation of the ticker symbol is not a guarantee that we will be listed on the NASDAQ. Listing on the NASDAQ is subject to approvals.

Under Regulation A+, a company has the ability to change its share price by up to 20%, without requalifying the offering with the SEC.